> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Blackfynn Adds Hahn to Company Board
- URL: https://www.fdaweb.com/blackfynn-adds-hahn-to-company-board/
- Published: 2021-02-23T12:00:00.000Z
- Updated: 2026-09-14T16:48:02.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5148725

Former FDA commissioner **Stephen Hahn** has joined clinical therapeutics Blackfynn’s board of directors. The firm says its approach to drug development is “grounded in its roots as a technology and data analysis company focused on neurodegenerative diseases. Blackfynn’s business model is to acquire and complete the development of clinical-stage drugs with the potential for significant, near-term impact for patients.” For example, on 2/18, Blackfynn announced that it had entered into an agreement with an undisclosed partner to acquire rights to a Phase 3-ready drug.